Apomorphine (Apokyn)

Apokyn (apomorphine) is covered only for Parkinson disease patients experiencing acute, intermittent hypomobility "off" episodes (end‑of‑dose wearing off and unpredictable on/off episodes); off‑label uses are excluded and IV administration is prohibited. Approval (up to 12 months) requires documentation of the PD diagnosis and off episodes, verification of no concomitant 5‑HT3 antagonists (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron), avoidance of anti‑dopaminergic antiemetics, and prescriber awareness of recommended antiemetic safety measures (e.g., trimethobenzamide).

"Diagnosis of Parkinson's disease"

Sign up to see full coverage criteria, indications, and limitations.